Live Stock Coverage: Will Acceleron Pharma Inc Short Squeeze Soon?

Live Stock Coverage: Will Acceleron Pharma Inc Short Squeeze Soon?

The stock of Acceleron Pharma Inc (NASDAQ:XLRN) is a huge mover today! About 96,550 shares traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 23.28% since March 9, 2016 and is uptrending. It has outperformed by 15.87% the S&P500.
The move comes after 7 months negative chart setup for the $1.13 billion company. It was reported on Oct, 12 by Barchart.com. We have $28.77 PT which if reached, will make NASDAQ:XLRN worth $90.40M less.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on November, 2. They expect $-0.57 EPS, down 58.33% or $0.21 from last year’s $-0.36 per share. After $-0.59 actual EPS reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts -3.39% EPS growth.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Barclays Capital initiated it with “Overweight” rating and $40 target price in Wednesday, April 27 report. As per Friday, January 15, the company rating was maintained by FBR Capital. FBR Capital maintained Acceleron Pharma Inc (NASDAQ:XLRN) on Monday, January 18 with “Outperform” rating. The stock has “Neutral” rating given by Janney Capital on Thursday, December 17. The company was initiated on Friday, November 20 by Oppenheimer. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Outperform” rating given on Monday, February 1 by Oppenheimer. The company was maintained on Monday, June 13 by Barclays Capital. As per Thursday, January 21, the company rating was initiated by Credit Suisse. Morgan Stanley initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, August 13 with “Overweight” rating. Citigroup initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, September 29 with “Neutral” rating.

According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.49 in 2016 Q2. Its down 0.65, from 2.14 in 2016Q1. The ratio turned negative, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
Savings Bank Of America De has invested 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Moreover, Barclays Public Ltd Co has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 41 shares. Loring Wolcott Coolidge Fiduciary Advisors Llp Ma reported 337 shares or 0% of all its holdings. Perceptive Advisors Lc holds 1.42% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 603,036 shares. The New York-based Comml Bank Of New York Mellon has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). California Employees Retirement Systems last reported 0% of its portfolio in the stock. Alliancebernstein L P reported 43,150 shares or 0% of all its holdings. Vanguard Grp Inc holds 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 1.65M shares. Brown Advisory holds 297,266 shares or 0.04% of its portfolio. Manufacturers Life Ins The has invested 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Novo A S has 2.45% invested in the company for 685,863 shares. Dekabank Deutsche Girozentrale last reported 18,900 shares in the company. Baker Bros L P last reported 28,765 shares in the company. Bessemer Grp holds 119 shares or 0% of its portfolio. Voya Inv Management Ltd Company last reported 0% of its portfolio in the stock.

Insider Transactions: Since May 18, 2016, the stock had 0 buys, and 10 insider sales for $45.10 million net activity. The insider Quisel John D sold $1.75 million. Another trade for 25,300 shares valued at $876,898 was made by MCLAUGHLIN KEVIN F on Friday, July 1. 100,000 shares with value of $3.31 million were sold by Knopf John L on Wednesday, May 18. Kumar Ravindra had sold 52,486 shares worth $1.78M on Thursday, October 6. $30.43M worth of Acceleron Pharma Inc (NASDAQ:XLRN) was sold by George Jean on Friday, September 30. On Friday, July 1 Ertel Steven D sold $1.12M worth of the stock or 32,270 shares. Another trade for 26,000 shares valued at $903,143 was made by Sherman Matthew L on Friday, July 1.

More recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: Streetinsider.com which released: “Acceleron Pharma (XLRN) CEO John Knopf to Retire; Habib Dable to Replace” on September 27, 2016. Also Businesswire.com published the news titled: “Acceleron Pharma Appoints Thomas McCourt to its Board of Directors” on July 25, 2016. Businesswire.com‘s news article titled: “Acceleron Announces Proposed Public Offering of Common Stock” with publication date: January 04, 2016 was also an interesting one.

XLRN Company Profile

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment